Dr Bret Scher and Dr David Ludwig (24 minutes)
Metabolic Mind - 9 May 2023
Harvard's Dr. David Ludwig addresses whether GLP-1 weight loss drugs like semaglutide, Wegovy & Ozempic should replace keto and low-carb diets for obesity, even in children. Or can low-carb diets complement drug treatments to reduce costs and long-term health risks and provide a path to life-long metabolic health?
Dr. Ludwig's new paper on the social justice implications of this issue is co-authored by Dr. Jens J. Holst, who has been credited with discovering the hormone GLP-1.
The GLP-1 medications semaglutide, Wegovy & Ozempic have taken the weight loss community by storm. They are even recommended for children and adolescents with obesity. But what are the long-term consequences of such widespread use, and why has the medical community seemingly abandoned dietary changes and behavioral support for medications and surgery? And what about the impact on long-term metabolic health and on questions of social justice?
